Ampliphi Biosciences Corp Share Price Nyse
Equities
APHB
US03211P2020
Biotechnology & Medical Research
Sales 2024 * | 4.54M 359M | Sales 2025 * | 2.75M 218M | Capitalization | 99.43M 7.86B |
---|---|---|---|---|---|
Net income 2024 * | -72M -5.69B | Net income 2025 * | -67M -5.3B | EV / Sales 2024 * | 21.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.2 x |
P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-2.12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.72% |
Managers | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 10/07/23 |
Richard Rychlik
DFI | Director of Finance/CFO | 68 | 04/09/23 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 25/10/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 11/02/20 | |
Joseph Patti
BRD | Director/Board Member | 60 | 08/05/19 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 31/03/21 |
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
+10.74% | 25.92B | |
-13.50% | 26.03B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |